Abstract:The identification of protective agents for the treatment of neurodegenerative diseases is the mainstay therapeutic goal to modify the disease course and arrest the irreversible disability progression. Pharmacological therapies synergistically targeting multiple pathogenic pathways, including oxidative stress, mitochondrial dysfunction, and inflammation, are prime candidates for neuroprotection. Combination or synergistic therapy with melatonin, whose decline correlates with altered sleep/wake cycle and impaired glymphatic "waste clearance" system in neurodegenerative diseases, has a great therapeutic potential to treat inflammatory neurodegenerative states. Despite the protective outcomes observed in preclinical studies, mild or poor outcomes were observed in clinical settings, suggesting that melatonin combinations promoting synergistic actions at appropriate doses might be more suitable to treat multifactorial neurodegenerative disorders. In this review, we first summarize the key melatonin actions and pathways contributing to cell protection and its therapeutic implication in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We remark the major controversies in the field, mostly generated by the lack of a common consensus for the optimal dosing, molecular targets, and toxicity. Then, we review the literature investigating the efficacy of melatonin combinations with approved or investigational neuroprotective agents and of melatonin‐containing hybrid molecules, both in vitro and in animal models of AD, PD, and MS, as well as the efficacy of add‐on melatonin in clinical settings. We highlight the rationale for such melatonin combinations with a focus on the comparison with single‐agent treatment and on the assays in which an additive or a synergistic effect has been achieved. We conclude that a better characterization of the mechanisms underlying such melatonin synergistic actions under neuroinflammation at appropriate doses needs to be tackled to advance successful clinical translation of neuroprotective melatonin combination therapies or melatonin‐based hybrid molecules.

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

Melatonin: A potential nighttime guardian against Alzheimer's

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials

Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin

Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology

Melatonin Ameliorates Cognitive Deficits Through Improving Mitophagy in a Mouse Model of Alzheimer's Disease

Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease

Novel Melatonin-Trientine Conjugate As Potential Therapeutic Agents for Alzheimer's Disease.

Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer’s disease

The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials

Melatonin and Sleep Disturbances in Alzheimer's Disease.

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

Melatonin improves cognitive dysfunction and decreases gliosis in the streptozotocin-induced rat model of sporadic Alzheimer's disease

Melatonin Attenuates Scopolamine-Induced Memory/Synaptic Disorder by Rescuing EPACs/miR-124/Egr1 Pathway

Melatonin Regulates Aβ Production/clearance Balance and Aβ Neurotoxicity: A Potential Therapeutic Molecule for Alzheimer’s Disease

Role of melatonin in regulating neurogenesis: Implications for the neurodegenerative pathology and analogous therapeutics for Alzheimer’s disease

Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer’s Disease: A Systematic Review and Meta-analysis

Melatonin protects against amyloid-β-induced impairments of hippocampal LTP and spatial learning in rats

Protective Effect of the Novel Melatonin Analogue Containing Donepezil Fragment on Memory Impairment via MT/ERK/CREB Signaling in the Hippocampus in a Rat Model of Pinealectomy and Subsequent Aβ1-42 Infusion

Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases